$11.00
Manufacturer: Ukraine
Prevention of manifestations of atherothrombosis in adults: in patients after myocardial infarction (the beginning of treatment – a few days, but no later than 35 days after the onset), ischemic stroke (the beginning of treatment – 7 days, but no later than 6 months after the onset ), or who have been diagnosed with peripheral arterial disease (arterial damage and atherothrombosis of the vessels of the lower extremities); in patients with acute coronary syndrome: with acute coronary syndrome without ST segment elevation (unstable angina or myocardial infarction without Q wave), including in patients who had a stent installed during percutaneous coronary angioplasty, in combination with acetylsalicylic acid; with acute myocardial infarction with an ST segment elevation in combination with acetylsalicylic acid (in patients receiving standard medication and who are shown thrombolytic therapy). Prevention of atherothrombotic and thromboembolic events in atrial fibrillation. Clopidogrel in combination with ASA is indicated for adult patients with atrial fibrillation, who have at least one risk factor for the occurrence of vascular events, who have contraindications for treatment with vitamin K antagonists (aVK) and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events including stroke.
Description
Trombonet (clopidogrel) coated tablets 75 mg №60
Composition and form of release
Active ingredient: clopidogrel.
Trombonet is produced in the form of tablets (75 mg).
Pharmacological properties
It is an antithrombotic agent. This drug disrupts platelet aggregation (pooling) by blocking the binding of adenosine diphosphate to receptors located on the platelet membrane, as well as activating glycoprotein IIb / IIIa receptors. The drug also helps to reduce platelet aggregation caused by other agonists, inhibits their activation by released adenosine diphosphate.
Indications
Trombonet is used to prevent manifestations of atherothrombosis:
- in individuals who have had myocardial infarction, ischemic stroke with diagnosed lesions of peripheral arteries (atherothrombosis of the vessels, lesion of the arteries of the lower extremities);
- in individuals with acute coronary syndrome: without elevation of S — T (non-Q-infarction, unstable angina), incl. in individuals who have undergone bypass surgery during coronary angioplasty; with the rise of S — T (in combination with acetylsalicylic acid).
Trombonet is also indicated for the prevention of thromboembolic, atherothrombotic events in atrial fibrillation.
Contraindications
You cannot use Trombonet:
- with liver failure;
- if you are allergic to clopidogrel;
- with intolerance to auxiliary components;
- with acute bleeding;
- children.
Trombonet 75 is prescribed with caution to patients with chronic renal dysfunction, risk of bleeding, hereditary decrease in the function of the isoenzyme CYP2C19, as well as to patients receiving acetylsalicylic acid, heparin, non-steroidal anti-inflammatory, glycoprotein IIb / IIIa inhibitors.
Application during pregnancy and lactation
During these periods, Trombonet is not prescribed.
Method of administration and dosage
Trombonet is administered orally, regardless of food.
The standard dose is 75 mg once a day.
With ACS without elevation of the S — T segment, a single loading dose of 300 mg is started once, and then 75 mg once a day. When used with acetylsalicylic acid, the risk of bleeding increases, so it is not recommended to exceed the dose of 100 mg. The maximum effect was usually achieved after 3 months of treatment.
With ACS with an increase in the S — T segment, 75 mg / day is prescribed, starting with a single loading dose of 300 mg. Treatment of persons over 75 years old begins without a loading dose.
For atrial fibrillation, a single dose of 75 mg is used.
Overdose
Overdose signs: prolongation of bleeding time, development of hemorrhagic complications.
Treatment: stopping bleeding, platelet transfusion.
Side effects:
- Changes in blood counts: eosinophilia, neutropenia, leukopenia, thrombocytopenic purpura, granulocytopenia, pancytopenia, aplastic anemia, agranulocytosis, severe thrombocytopenia, anemia.
Immune disorders: serum sickness, cross-hypersensitivity with thienopyridines (prasugrel, ticlopidine), anaphylactoid reactions. - Mental disorders: confusion, hallucinations.
- Neurological disorders: paresthesias, intracranial bleeding, headache, dizziness, change in taste.
- Ophthalmic disorders: ocular, conjunctival, retinal bleeding.
- Otolaryngological disorders: vertigo.
- Cardiovascular disorders: hematoma, significant hemorrhage, vasculitis, bleeding from the surgical wound, arterial hypotension.
- Respiratory disorders: interstitial pneumonitis, epistaxis, pulmonary bleeding, hemoptysis, bronchospasm, eosinophilic pneumonia.
- Digestive disorders: gastrointestinal bleeding, abdominal pain, diarrhea, ulcerative lesions, gastritis, nausea, flatulence, constipation, retroperitoneal hemorrhage, retroperitoneal or gastrointestinal bleeding, pancreatitis, ulcerative or lymphocytic colitis, hepatitis, stomatitis, abnormal results liver, acute liver failure.
- Dermatological disorders: subcutaneous hemorrhage, pruritus, bullous dermatitis, rash, purpura, angioedema, exfoliative rash, drug-induced hypersensitivity syndrome, urticaria, DRESS syndrome, lichen planus, eczema.
- Musculoskeletal disorders: arthralgia, arthritis, hemarthrosis, myalgia.
- Urinary disorders: glomerulonephritis, hematuria, increased blood creatinine levels.
- General: fever.
Storage conditions and period
Store Trombonet at 15-25 degrees Celsius, maximum storage time is two years.
Recent Reviews